Research analysts at Oppenheimer initiated coverage on shares of 89bio (NASDAQ:ETNB) in a report issued on Monday, BenzingaRatingsTable reports. The brokerage set an “outperform” rating and a $60.00 price target on the stock. Oppenheimer’s price objective points to a potential upside of 109.79% from the stock’s previous close.
A number of other research analysts also recently weighed in on ETNB. Bank of America initiated coverage on shares of 89bio in a research report on Monday. They issued a “neutral” rating and a $33.00 price objective for the company. Royal Bank of Canada started coverage on 89bio in a research report on Monday. They set an “outperform” rating and a $36.00 target price on the stock. Finally, Leerink Swann began coverage on 89bio in a research report on Monday. They set an “outperform” rating on the stock. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. 89bio has an average rating of “Buy” and a consensus target price of $46.00.
NASDAQ:ETNB opened at $28.60 on Monday. 89bio has a 1-year low of $16.60 and a 1-year high of $46.19.
89bio Company Profile
89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate, BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 that is being developed for the treatment of nonalcoholic steatohepatitis.
Featured Article: How does equity income fit into an investing strategy?
Receive News & Ratings for 89bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 89bio and related companies with MarketBeat.com's FREE daily email newsletter.